GENERAL29 Sept 2026
Natco Pharma hikes investment in US-based eGenesis to $16.7 million
Natco Pharma has raised its planned investment in US biotech firm eGenesis to $16.70 million, about ₹139 crore, from $14 million. Natco Pharma (Canada) Inc will put in $13.70 million, while Natco Pharma USA LLC adds $3 million. The cash buys convertible promissory notes paying 8 per cent interest, compounded annually, with completion expected by October 31. Total investment will touch $24.70 million.
Key Statutory Highlights
- Natco Pharma has increased its proposed investment in US-based biotechnology firm eGenesis Inc to $16.70 million from the earlier disclosed $14 million.
- Natco Pharma (Canada) Inc will invest $13.70 million and Natco Pharma USA LLC will contribute $3 million in cash for convertible promissory notes.
- Those notes carry an interest rate of 8 per cent compounded annually, and the company's total investment in eGenesis will rise to $24.70 million.
Actionable Advice for Taxpayers / Founders:If you hold Natco Pharma shares, read the regulatory filing carefully and treat it as company information, not a buy or sell signal. Speak to your own advisor before taking any investment decision.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: